DDInter655 DDInter927
An anthracycline which is the 4&#39;-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Epirubicin {u} (Compound) treats {v} (Disease) ovarian cancer
Epirubicin {u} (Compound) binds {v} (Gene) YWHAG
Epirubicin {u} (Compound) upregulates {v} (Gene) SCPEP1
Epirubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Epirubicin {u} (Compound) downregulates {v} (Gene) KPNA2
Epirubicin {u} (Compound) causes {v} (Side Effect) Haemoptysis
Epirubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Epirubicin (Compound) resembles Doxorubicin (Compound)
Epirubicin (Compound) resembles Valrubicin (Compound)
Epirubicin (Compound) treats ovarian cancer (Disease)
Epirubicin (Compound) binds YWHAG (Gene)
Epirubicin (Compound) upregulates SCPEP1 (Gene)
Epirubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Epirubicin (Compound) downregulates KPNA2 (Gene)
Epirubicin (Compound) causes Haemoptysis (Side Effect)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin